# Compare Retatrutide, Tesamorelin and MOTS-c — Peptide Supplied

> A side-by-side comparison of three Metabolic & Weight Research peptides — retatrutide, tesamorelin, and MOTS-c — across peptide class, evidence base, administration studied, regulatory status, and key caution.

Where the three metabolic research peptides converge, where they diverge, and how far the evidence behind each actually reaches.

## The short version

This page lines up [retatrutide](/retatrutide), [tesamorelin](/tesamorelin), and [MOTS-c](/mots-c) on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was given in studies, its regulatory standing, and its single most important caution. The headline is blunt. All three sit in the metabolic and weight-management research space, but they are at very different clinical stages: retatrutide has Phase 2 human efficacy data and an ongoing Phase 3 program but is not approved; tesamorelin is approved — but only for a specific HIV-related indication; and MOTS-c has no human intervention trials at all. None is presented here with a dose.

## The comparison matrix

| Dimension | Retatrutide | Tesamorelin | MOTS-c |
| --- | --- | --- | --- |
| Peptide class | Investigational GIP/GLP-1/glucagon receptor triple agonist (39 aa) | Synthetic GHRH analogue / growth hormone-releasing factor (44 aa) | Mitochondrial-derived peptide (16 aa), AMPK activator |
| Most-studied in | Obesity, type 2 diabetes, MASLD (human clinical trials) | HIV-associated lipodystrophy (human RCTs) | Skeletal muscle metabolism, aging, exercise (animal + cell studies) |
| Evidence base (model) | Phase 1/2 human trials; Phase 3 ongoing [1][4][5] | Five human RCTs (HIV population); one healthy-volunteer GH study [8][10][11] | Cell studies; mouse models; one human observational cohort [13][14][15][16] |
| Administration studied | Subcutaneous injection, once weekly [4][6] | Subcutaneous injection, once daily [8][10][12] | Intraperitoneal / subcutaneous in animals; no human PK data [13][16] |
| Regulatory / WADA status | Not approved by any regulator (investigational, Phase 3); WADA status: not specifically listed but unapproved | FDA-approved for HIV lipodystrophy only (NDA 022505, 2010); WADA S2 prohibited | Not FDA-approved; WADA prohibited (hormone/metabolic modulator category) |
| Key caution | Unapproved; gray-market supply is unverified; GI AEs and heart-rate increase in trials [4] | Off-label outside HIV lipodystrophy; fat reaccumulates on discontinuation [12] | Entirely preclinical for efficacy; no human intervention data [15] |

## Peptide class

The three are architecturally and mechanistically distinct. Retatrutide is a 39-amino-acid synthetic GIP-backbone peptide with fatty-acid acylation for albumin binding; it acts directly at three receptor types in the gut, brain, and pancreas [1][2]. Tesamorelin is a 44-amino-acid synthetic GHRH analogue that acts on the pituitary to release the body's own GH, which then drives visceral fat mobilization via the GH/IGF-1 axis — an indirect mechanism one step removed from the tissue target [11]. MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, unique in origin and mechanism: it inhibits an intracellular biosynthetic pathway to activate AMPK, the cell-autonomous energy sensor, and in stress conditions translocates directly into the nucleus [15][17].

## Most-studied in

Each peptide has a primary research territory. Retatrutide is studied in human populations with obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease — the broadest and most clinically relevant scope of the three [3][4][5]. Tesamorelin's evidence base is anchored in HIV-associated lipodystrophy, where antiretroviral therapy causes distinctive fat redistribution; the visceral and hepatic fat data are strong within that population, but that population is specific [8][10][12]. MOTS-c is studied in skeletal muscle metabolism, metabolic disease models, physical performance, and aging — almost entirely in mice and cell cultures, with one human biomarker cohort study [13][14][16].

## Evidence base (model)

This is where the three genuinely separate. Retatrutide has the most robust human efficacy data: two completed Phase 2 RCTs with direct body-weight, HbA1c, and liver-fat outcomes, plus Phase 1 PK/safety, Phase 3 underway [1][4][5]. Tesamorelin has five completed RCTs in HIV populations, a safety monograph with an "unlikely hepatotoxin" classification, and a long real-world clinical use record since 2010 — but exclusively in that indication [8][9][12]. MOTS-c has no completed human efficacy trials; one prospective cohort study measured circulating MOTS-c as a biomarker of mortality and cardiovascular risk in hemodialysis patients [14] — that is observational association, not interventional evidence.

## Administration studied

Routes and schedules reflect the research questions. Retatrutide in Phase 2 used once-weekly subcutaneous injection; PK work established the approximately 6-day half-life that makes weekly dosing feasible [4][6]. Tesamorelin in its clinical trials was given as once-daily subcutaneous injection at 2 mg/day; the trial durations ran from 6 months to 52 weeks [10][12]. MOTS-c in animal studies used intraperitoneal injection at doses in the range of 0.5-15 mg/kg/day; there are no validated human pharmacokinetics, no published human dose-response data, and no human intervention trial to establish a route or schedule [13][16].

## Regulatory / WADA status

Regulatory status is the sharpest differentiator on this desk. Retatrutide is investigational and not approved by any regulatory agency worldwide as of mid-2026 [4]. Tesamorelin is FDA-approved as a prescription drug (NDA 022505, November 2010), but that approval is narrowly defined: HIV-infected adults with antiretroviral-therapy-related lipodystrophy [9]. MOTS-c has no regulatory approval for any use and is sold only as a research chemical. On WADA status: tesamorelin is explicitly prohibited in sport (S2 category — peptide hormones, growth factors, related substances and mimetics) [9]; MOTS-c is treated as prohibited by anti-doping authorities; retatrutide is not specifically listed by WADA but as an unapproved investigational agent should be treated cautiously in any sporting context.

## Key caution

Each peptide carries a defining practical caveat. For retatrutide it is the combination of "not yet approved" and an active gray market: material obtained outside supervised trials is not verified to be authentic, pure, or sterile, and the FDA issued over 50 warning letters to vendors in 2025 [4]. For tesamorelin it is the indication boundary: evidence outside HIV lipodystrophy is limited, off-label use lacks large RCT support, and the fat-reaccumulation on discontinuation means the benefit is not durable off-treatment [12]. For MOTS-c it is the complete absence of human intervention evidence: community and vendor claims about metabolism and performance in humans are built on animal and cell data with no human trial to anchor them [15]. Taken together: the most compelling preclinical story (MOTS-c), the strongest human signal (retatrutide), and the narrowest but most established approval (tesamorelin) illustrate the range of how far research peptides can travel — and how different those distances are.

---

A practitioner's reading desk for metabolic peptide research — citations and mechanism, not doses and not advice.